This post by JB re updated data For ceritinib in the WCLC conference only reinforces the case for Brigatinib to be BIC in the not so distant future. The last sentence that refers to ceritinib as a poor choice is a clincher for Brigatinib. Here is the link.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.